Date:12/13/2011

e research, development and commercialization of pharmaceutical products.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.  No forward-looking statement can be guaranteed.  Among other risks, there can be no guarantee that the compound described in this release will move from exploratory development into full product development, that clinical trials of this compound will support a regulatory filing, or that the compound will receive regulatory approval or become a commercially successful product. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2010, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Simcere Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management's current views and expectations with res
'/>"/>

SOURCE Simcere Pharmaceutical Group Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
2. Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011
3. Simceres Iremod Receives SFDA New Drug Approval
4. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
6. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
7. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
8. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
9. Simcere Announces Recent Progress of Qiangkes Registration
10. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results